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Abstract: A commonly reported definition of polypharmacy is the numerical definition of 5 or more medications daily, and
definitions have ranged from 2 or more to 11 or more medications. In this case report, an extreme case of polypharmacy is presented,
highlighted by the inordinate number of drugs used over time throughout the patient’s care. A 48-year-old African American female
with multiple comorbidities experienced a serious adverse drug event (ADE) prompting reporting to MedWatch, the US Food and
Drug Administration’s adverse drug event reporting system. The patient’s concomitant medications included 146 drug entities,
across 82 therapeutic drug categories. It is apparent that the greatest influence on the occurrence of polypharmacy was the presence
of multiple comorbidities, and treatment centered around addressing each morbidity with drug therapy. This case illustrates the
insidious nature of polypharmacy and raises questions as to the appropriate progression and limits on the use of multiple
medications.
Keywords: polypharmacy, adverse drug event, comorbidity, multiple medications, food and drug administration, MedWatch

Introduction
Polypharmacy has been described as “one of the greatest prescribing challenges in general practice”.1 Several harmful
consequences have been identified related to polypharmacy, which include, but are not limited to, greater health care
costs, an increased risk of adverse drug events (ADEs), drug interactions, medication non-adherence, and reduced
functional capacity.2 Aside from being a major problem in clinical practice, just identifying a uniform definition of
polypharmacy has been challenging. In one report, a total of 138 definitions of polypharmacy and associated terms were
obtained”.3 A commonly reported definition of polypharmacy is the numerical definition of 5 or more medications daily,4
and definitions have ranged from 2 or more to 11 or more medications.3
As well as the lack of congruence for the definition of polypharmacy, reporting on the prevalence of polypharmacy
exists to varying degrees of consistency.
Quinna and Shah report that concomitant use of multiple prescription drugs is increasingly common, with 10% of the
population and 30% of older adults in the US taking five or more drugs simultaneously.5
According to the Slone Epidemiology Center in Boston, MA (2006), in a given week, an average of 82% of adults in
the US are taking at least one medication (prescription or nonprescription drug, vitamin/mineral, herbal/natural supplement), and 29% are taking five or more.6
As recently as August 2019, Hales et al reported that nearly 7 in 10 adults aged 40–79 used at least 1 prescription
drug in the past 30 days in the US (69.0%) and Canada (65.5%), and approximately 1 in 5 used at least 5 prescription
drugs (22.4% in the US and 18.8% in Canada).7
The occurrence of polypharmacy is more pronounced in older adults. Woodruff reports that 44% of men and 57% of
women older than age 65 take five or more medications per week; about 12% of both men and women take 10 or more
medications per week. These agents include both prescription and over-the-counter (OTC) preparations, such as vitamin
and mineral supplements and herbal products.8 This coincides with a recent account by Nguyen et al who report an
average rate of 40% to 50% in this population.9
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In this case report, an atypical case of extreme polypharmacy is presented, highlighted by the inordinate number of
drugs used over time throughout the patient’s care. The source of information for the case is MedWatch, the US Food and
Drug Administration’s adverse drug event reporting system.10 The FDA Adverse Event Reporting System (FAERS)
database includes the MedWatch narratives submitted by healthcare providers and patients with identifying details
removed. Using the Freedom of Information Act (FOIA), a copy of the individual case report was obtained from the
FDA, which includes a narrative where reporters describe the clinical (adverse) event in their own words.11 The
polypharmacy in this case raises questions as to the appropriate use of drugs in patients with multiple comorbidities.

Case Report
A 48-year-old African American female with multiple comorbidities experienced a serious adverse drug event (ADE)
prompting reporting to MedWatch. Possible nephrogenic systemic fibrosis (NSF) was observed in the patient after
receiving contrast media. According to clinical notes, on eight different occasions from 1991 to 2008, the patient received
Omniscan® (gadodiamide) for the indication of “fullness in the right neck”, a gadolinium agent (type not specified) for
the indication of left breast mass and liver cancer, and Magnevist® (gadopentetate dimeglumine) for the indications of
headache to rule out central nervous system Lupus, questionable stroke, and spasmatic weakness. On March 25, 2014,
The FDA received an ADE report by clinicians through the FDA’s MedWatch surveillance reporting system. At the time
the report was submitted, the patient’s history and medical condition were noted.
Relevant past medical history with year of occurrence included: end stage renal disease (ESRD) (1984, 1999), lupus
nephritis (1984), first cadaveric kidney transplant (unspecified date), removal of first renal transplant (unspecified date),
myocardial infarction (unspecified date), Lupus cerebritis (1999), bilateral femoral chondromalacia patellae (2000),
partial parathyroidectomy (unspecified date), atrial fibrillation, second cadaveric renal transplant (unspecified date),
chronic allograft nephropathy (2007), third renal transplant evaluation (unspecified date), transplant failure of second
transplant (2008), and nontoxic multinodular goiter (2010).
At the time of the report, concurrent medical conditions with year of occurrence included uncontrolled hypertension,
systemic lupus erythematosus with End-Stage Renal Disease (ESRD) (1984), various stages of chronic kidney disease
(1998) peritoneal dialysis, hepatitis C (1995), seizures (1999), diabetes mellitus induced by Dapsone (diamino-diphenyl
sulfone) (2002), overactive parathyroid (2003), nerve damage, poor circulation, rotator cuff disease in both shoulders,
osteoporosis (both wrists and spine), arthritis (both wrist and spine), gout, human papilloma virus (HPV), peritoneal
dialysis (1998 to 2002 and Jun 2008 onwards), cytomegalovirus (CMV), Hepatitis B, secondary hyperparathyroidism,
sensory polyneuropathy axonal and Raynaud’s disease.
Concomitant medications included 146 drug entities, across 82 therapeutic drug categories. The medications listed
included 8 duplicate entries, identified separately by brand and generic name. Dosage forms included oral, injectable,
topical, nasal, ophthalmic, and intraocular drug products. In addition, the patient had been taking vitamins, minerals, and
nutritional supplements. The information is presented in Table 1.

Discussion
This case illustrates the insidious nature of polypharmacy and raises questions as to the appropriate progression and
limits on the use of multiple medications. In the context of patients afflicted by polypharmacy, the case described may be
extreme, and perhaps even viewed as an outlier. Yet, the case illustrates several important issues that healthcare
practitioners should consider when caring for patients on drug therapy for multiple health conditions.
The US Food and Drug Administration (FDA) maintains one of the largest government databases in the country,
known as the FDA Adverse Event Reporting System, or FAERS. It is comprised of drug safety reports that have been
submitted to the FDA through the “MedWatch” reporting program.12 Reports can be submitted to the FDA by consumers,
health care providers, and drug manufacturers. A copy of an individual case report can be obtained from the FDA, which
includes a narrative where reporters describe the adverse event in their own words based on observations.13 The original
MedWatch report of this case is provided as Supplemental Online Material.
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Table 1 Atypical Case of Extreme Polypharmacy: Concomitant Medications (Drug* and Therapeutic Category**)
Drug

Drug

Drug

Drug

[Therapeutic Category]

[Therapeutic Category]

[Therapeutic Category]

[Therapeutic Category]

1.Absorbase cream

11. Atarax (hydroxyzine)

21. Calcium (dosage form

31. Claritin (loratadine)

41. Cytoxan intravenous

(topical) [Topical
emollients]

[Antihistamines,
Miscellaneous anxiolytics,

not specified) [Minerals]

[Antihistamines]

(IV) [Alkylating agents]

Drug
[Therapeutic
Category]

sedatives and hypnotics]
2. Acular eyedrops

12. Atgam (antithimocyte

22. Calcium gluconate

32. Clobetasol 0.05 percent

42. Dapsone [Antileprotic

(ketorolac

immunoglobulin) [Selective

[Minerals and electrolytes]

cream (clobetasol

agent]

tromethamine)
[Ophthalmic anti-

immunosuppressants]

propionate)
[Corticosteroids]

inflammatory agents]
3. Acyclovir [Purine

13. Avapro (irbesartan)

23. Cardizem (diltiazem)

33. Clonidine

43. Decadron

nucleoside
antibiotics]

[Angiotensin receptor
blockers]

[Calcium channel blocking
agents, Group IV

[Antiadrenergic agents,
centrally acting]

(dexamethasone) 0.5 ml
Topical [Glucocorticoid]

antiarrhythmics]
4. Ambien (zolpidem

14. Benadryl

*24. Cardura (doxazosin

34. Colace (docusate

44. Dilantin (phenytoin)

tartrate) [Anxiolytics,

(diphenhydramine

mesilate), [Antiadrenergic

sodium) [Laxatives]

[Group I antiarrhythmics,

sedatives and
hypnotics]

hydrochloride)
[Antihistamines,

agents, peripherally acting]

Hydantoin anticonvulsants]

Anxiolytics, sedatives,
hypnotics]
5. Amiodarone

15. Betadine 5 percent

25. Celestone

35. Compazine

45. Diovan (valsartan)

[Group III
antiarrhythmics]

Ophthalmic (povidone
iodine) [broad-spectrum

(betamethasone)
[Glucocorticoids]

(prochlorperazine edisylate)
[Phenothiazine antiemetics/

[Angiotensin receptor
blockers]

antipsychotics]

microbicide]
*6. Amlodipine

16. Bicitra (Shohl’s)

26. CellCept

36. Coumadin (warfarin

46. Diphenoxylate

[Calcium channel

[Alkalinizing agents,

(mycophenolate mofetil)

sodium) [Coumarins and

[Antidiarrhea Agents]

blocking agents]

Minerals and electrolytes]

[Selective
immunosuppressants]

indandiones]

7. Amoxicillin
[Aminopenicillins]

17. Bisacodyl [Laxatives]

27. Cephalexin [First
generation cephalosporins]

*37. Cozaar (losartan
potassium) [Angiotensin

47. Diprolene ointment
(betamethasone

receptor blockers]

dipropionate) [Topical
steroids]

8. Amphojel

18. Bumex (bumetanide)

28. Cholecalciferol (Vitamin

*38. Cyclobenzaprine

*48. Doxazosin

(aluminum
hydroxide) [Antacids

[Loop diuretics]

D3) [Vitamins]

[Skeletal muscle relaxants]

[Antiadrenergic agents,
peripherally acting]

9. Aranesp

19. Calci-Mix (calcium

29. Cholestyramine-Lite

39. Cyclosporine

49. Ecotrin (acetylsalicylic

(darbepoetin alfa)

carbonate) [Antacids,

[Bile acid sequestrants]

[Calcineurin inhibitors]

acid) [Platelet aggregation

[Recombinant human
erythropoietins]

Minerals and electrolytes]

10. Aspirin
(acetylsalicylic acid)

*20. Calcitriol (active form
of vitamin D) [Vitamins]

Phosphate binders]

inhibitors, Salicylates]

30. Ciprofloxacin
[Quinolones]

40. Cytovene (ganciclovir)
[Purine nucleosides]

50. Epinephrine [Adrenergic
bronchodilators,

[Platelet aggregation

Catecholamines,

inhibitors, Salicylates]

Vasopressors]

(Continued)
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Table 1 (Continued).
Drug

Drug

Drug

Drug

[Therapeutic
Category]

[Therapeutic Category]

[Therapeutic Category]

[Therapeutic Category]

[Therapeutic Category]

*51. Epogen (epoetin
alfa) [Recombinant

61. Halcion (Triazolam)
[Benzodiazepines]

71. Insulin [Insulins]

81. Lidocaine [Group I
antiarrhythmics, Local

91. Nephrocaps (solvito N)
[Vitamin and mineral

injectable anesthetics]

combinations]

82. Lipitor (atorvastatin

92. Nephro-Vite (solvito N)

calcium) [Statins]

[Vitamin and mineral
combinations]
93. Netilmicin
[Aminoglycosides]

Drug

human
erythropoietins]
72. Interferon [Interferons]

52. Fentanyl

62. Halog (halcinonide)

[Narcotic analgesics]

cream 0.1 percent [Topical
steroids]

53. Ferrlecit (IV iron)
[Iron products]

63. Healon intraocular
(hyaluronate sodium)

73. Iopidine gtts
(apraclonidine) [alpha-2-

83. Lopressor (metoprolol
tartrate) [Cardioselective

[Opthalmic surgical agents]

adrenergic agonists

beta blockers]

ophthalmic]
54. Ferrous Sulfate

64. Hectorol

[Iron products]

(doxercalciferol) [Vitamins]

*55. Flexeril [Skeletal
muscle relaxants]

65. Hexavitamin Tablets
(kapasovit) [Vitamin and

*84. Loratadine

94. Nexium (esomeprazole

[antihistamines]

magnesium) [Proton pump
inhibitors]

75. Kayexalate (sodium
polystyrene sulfonate)

*85. Losartan potassium
[Angiotensin receptor

95. Niferex (ferroflycine
sulfate complex) [Iron

mineral combinations]

[Cation exchange resins]

blockers]

products]

56. Flonase

66. Hismanal (astemizole)

76. Kaopectate (bismuth

86. Miralax (macrogel)

96. NitroQuick (glyceryl

(fluticasone

[Antihistamines]

subsalicylate)

[Laxatives]

trinitrate) [Antianginal
agents, Vasodilators]

[Antidiarrheals]

propionate) [Nasal
steroids]
57. Fluconazole
(Diflucan) [Azole

74. Iron [Iron products]

67. Hydrochlorothiazide
[Thiazide diuretics]

77. K-Phos (potassium
phosphate monobasic)

87. Multivitamin
[Multivitamins]

*97. Norvasc (amlodipine
besilate) [Calcium channel
blocking agents]

[Minerals and electrolytes]

antifungals]
58. Folic Acid

68. Imdur (isosorbide

88. Mycophenolic Acid

98. Nystatin [Mouth and

[Vitamins]

mononitrate) [Antianginal

[Selective

throat products, Polyenes

agents]

immunosuppressants]

78. Lactulose [Laxatives]

59. Fosamax

69. Imodium (loperamide

79. Lasix (furosemide)

89. Nasonex (mometasone

99. OKT3 (muromonab

(alendronate sodium)
[Bisphosphonates]

hydrochloride)
[Antidiarrheals]

[Loop diuretics]

furoate) [Nasal steroids]

CD-3) [Monoclonal
Antibody]

60. Gentamicin drops

70. Imuran (azathioprine)

80. Levsin (hyoscyamine

90. NebuPent (pentamidine

100. Os-Cal (calcium

[Aminoglycosides

[Antirheumatics,

sulfate) [Anticholinergics/

isethionate) [Inhaled anti-

carbonate) [Minerals and

Immunosuppressants]

antispasmodics]

infectives]

electrolytes]

(Continued)
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Table 1 (Continued).
Drug

Drug

Drug

Drug

[Therapeutic
Category]

[Therapeutic Category]

[Therapeutic Category]

[Therapeutic Category]

[Therapeutic Category]

101. Oxycodone
[Narcotic analgesics]

111. Procardia (nifedipine)
[Calcium channel blocking

121. Spironolactone
(Aldactone) [Aldosterone

131. Vancomycin
[Glycopeptide antibiotics]

141. WelChol (colesevelam
hydrochloride) [Bile acid

agents]

receptor antagonists,

Drug

sequestrants]

Potassium-sparing
diuretics]
102. Paxil (paroxetine
hydrochloride)

*112. Procrit (epoetin alfa)
[Recombinant human

122. TAC (triamcinolone
acetonide)

132. Venofer and Iron
Sucrose (saccharated iron

142. Zantac (ranitidine
hydrochloride) [H2

[Selective serotonin

erythropoietins]

[Glucocorticoids topical]

oxide) [Iron products]

antagonists]

103. Percocet

*113. Prograf (tacrolimus)

*123. Tacrolimus

133. Versed (midazolam

143. Zemplar (paricalcitol)

[Narcotic analgesic
combinations]

[Calcineurin inhibitors]

[Calcineurin inhibitors]

hydrochloride)
[Benzodiazepines]

[Vitamins]

104. Persantine
(dipyridamole)

114. Pyridoxine [Vitamins]

124. TBEC (pantoprazole
sodium) [Proton pump

134. Vibramycin
(doxycycline hyclate)

144. Zetia (ezetimibe)
[Cholesterol absorption

inhibitors]

[Tetracyclines,

inhibitors]

reuptake inhibitors]

[Cardiac stressing

Antimalarials]

agents, Platelet
aggregation
inhibitors]
105. Phosphorus

115. Quinine [Antimalarial

125. Temazepam (Restoril)

135. Vicodin [Narcotic

145. Zocor (simvastatin)

[Minerals and

quinolines]

[Benzodiazepines]

analgesic combinations]

[Statins]

106. Plaquenil

116. Renagel (sevelamer

126. Tetravisc Topical Gel

136. Vioxx (rofecoxib)

146. Zovirax [Antiviral,

(hydroxychloroquine
phosphate)

hydrochloride) [Phosphate
binders]

(tetracaine hydrochloride)
[Ophthalmic anesthetics]

[Cox-2 inhibitors]

Purine nucleosides]

107. Potassium
chloride [Minerals

117. Ribavirin [Inhaled antiinfectives, Purine

127. Timoptic gtts (timolol
maleate) [Ophthalmic

137. Vitamin B12
(cyanocobalamin) [Vitamins]

and electrolytes]

nucleosides]

glaucoma agents]

108. Prednisone

*118. Rocaltrol (calcitriol)

128. TriLyte Oral Solution

*138. Vitamin B6

[Glucocorticoids]

[Vitamins]

(movicol) [Osmotic

(pyridoxine hydrochloride)

laxatives]

[Vitamins]

electrolytes]

[Antimalarial
quinolines,
Antirheumatics]

109. Prevacid

119. Simethicone

129. Tums (calcium

139. Vitamin D

(lansoprazole)
[Proton pump

[Antiflatulents]

carbonate) [Antacids,
Minerals and electrolytes]

(ergocalciferol) [Vitamins]

110. Prilosec

120. Sirolimus (Rapamune)

130. Valium (Diazepam)

140. Vitamin E (tocopherol)

(omeprazole)
[Proton pump

[MTOR inhibitors, selective
immunosuppressants]

[Benzodiazepines,
Anticonvulsants]

[Vitamins]

inhibitors]

inhibitors]
Notes: *Both brand and generic drug name listed as separate entities. **References: PDR. Prescribers’ Digital Reference. https://www.pdr.net/.Drugs.com. https://www.
drugs.com/.
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The focus of this case report is on polypharmacy specifically as it relates to the large quantity of prescription drugs
used by an individual patient in their treatment. In the report, it is difficult to discern the presence of inappropriate use of
medication(s), or use of medications without a clinical indication, which also have been used to define polypharmacy.4
Other similar cases on high numbers of prescribed drugs considered to be extreme have appeared in the medical
literature.
Agarwal and Agarwal (2013) report an extreme case of polypharmacy in a patient with schizophrenia.14 A 67-yearold female patient was taking 32 different medications for various comorbid conditions. The patient’s drug regimen
included 38 to 41 pills per day, oral liquid medication 2 to 5 per day and applying two lotions for a total of 4 times
per day. The authors conclude that all of the medications appeared to be clinically warranted, although “runaway”
polypharmacy can result from a patient’s comorbid conditions and seeing different specialists.
Nechba et al describe the case of an 85-year-old female who had been taking the 6 different drugs for an extended
period of time: amlodipine, valsartan, hydrochlorothiazide, lysine acetylsalicylate, simvastatin, and trimetazidine.15 At
a later time, she presented thoracic pain and received 3 more drugs: propranolol, tramadol, and paracetamol. One week
later, she developed a diffuse skin lesion, which was treated with an oral corticosteroid. The authors conclude that
consequences of polypharmacy can be serious, and as highlighted in this case, elderly patients with multiple comorbidities are at risk of experiencing adverse drug events, and perhaps iatrogeny.
In a case series study on patients seen in outpatient clinical practice, Finkelstein et al describe the case of a 74-yearold Dominican woman with a history of hypertension, diabetes, hyperlipidemia, diastolic heart failure, and asthma for 30
years on 26 different medications.16 The patient underwent pharmacogenetic (PGx) testing by a treating physician in
order to optimize her therapy. The decision to change or eliminate potentially inappropriate medications in this patient
was complicated by the complex interaction of polypharmacy and lack of clear evidence-based guidelines for optimal
drug changes under such conditions.
Gareri et al report the case of an 81-year-old man with a clinical history of diabetes, blood hypertension, non-valvular
atrial fibrillation, chronic obstructive pulmonary disease, osteoarthritis, anxiety, and depression.17 The patient was taking
11 different drugs daily. The authors conclude that prudent deprescribing in older adults is needed and avoiding
potentially inappropriate drugs. The authors assert that drug-induced symptoms are the second most frequent medical
problem that the geriatrician encounters, and collaboration with a pharmacologist can help to optimize pharmacotherapy
by deprescribing inappropriate agents.
Similar cases of patients with multiple comorbidities on multiple medication regimens ranging from 11 to 28 different
drugs can be found in the medical literature.9,18,19 In terms of sheer numbers, the case described here appears to exceed
all others for excessive medication use.

Determinants of Polypharmacy
Polypharmacy is a multifaceted healthcare issue, and as illustrated in this case, several risk factors exist increasing
a patient’s susceptibility to polypharmacy. Determinants of polypharmacy include patient-related factors such as having
multiple medical conditions or comorbidities, in particular, chronic mental health conditions.20
Polypharmacy is more likely to take place in the elderly, particularly for individuals residing in a long-term care
facility, although it has been observed to occur in younger, at-risk populations predisposed to medical conditions.20 With
increasing numbers of older adults in the population, the prevalence of chronic medical conditions is also increasing. And
an ageing population with increasing frailty often necessitates the use of multiple medications.21
Determinants of polypharmacy may also include medical conditions may be managed by multiple providers with
different specialties and subspecialties who may prescribe similar medications.22
Healthcare systems where care is delivered have been observed to play a role in the occurrence of polypharmacy.
Processes include operational factors such as fragmented care and a loss of accountability in medication management.
Poorly updated medical records, automated refill services, and prescribing to meet disease-specific quality metrics have
been implicated in occurrence of polypharmacy.23
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Some, if not several, of these factors likely played a role in the occurrence of the patient’s polypharmacy. In this case,
it is apparent that the greatest influence on the occurrence of polypharmacy was the presence of multiple comorbidities,
and treatment centered around addressing each morbidity with drug therapy.
Many patients suffering from a chronic disease condition may also endure concomitant illnesses, or comorbidities.24
Clinical treatment guidelines mainly focus on single disease conditions and often do not take into account patients who
have comorbidities.25 Using guidelines for single conditions can pose problems to clinicians treating, and patients with,
comorbidities, as patients with multiple medical conditions often have different healthcare needs.26
Increasing numbers of patients are prescribed complicated prevention regimens not just to treat each condition, but to
reduce their future risk of serious medical events such as diabetes, stroke, and coronary events.27,28 It is not uncommon
for patients with multiple comorbidities to be prescribed multiple medications to reduce long-term risk for those
conditions. Recommended guidelines for treating each condition often are associated with drug therapy management
and once a patient starts a medication, it may not be discontinued even though it may no longer be of benefit.20,29

Conclusion
For this case report, the information source is MedWatch, and reports are limited in the amount of detail about a patient’s
condition.30 The intent of this report is not necessarily to describe a rare condition, but to characterize a set of health
problems remarkable for their occurrence and concomitant medication use. Based on the observations recounted by
clinicians, it is not clear if any of the patient’s illnesses were caused by treatment with excessive medications.
This case illustrates extreme polypharmacy. Although all medications may be clinically warranted, co-morbid
conditions and multiple prescribers can result in polypharmacy, which can be problematic to patients if left unchecked.
Non-compliance, drug-drug interactions and serious side effects can result from extreme polypharmacy. This is best
summed up by Rowhani and Iglseder, “Although clinicians are aware of multimorbidity and the risks of polypharmacy,
the dilemma of how to treat the frail and multimorbid without subjecting patients to under-treatment, or indeed overtreatment, remains”.19
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